Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Director William R. Ringo sold 600 shares of the stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $45.33, for a total value of $27,198.00. Following the transaction, the director now owns 600 shares of the company’s stock, valued at $27,198. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($1.58) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.15) by ($0.43). The firm had revenue of $7.80 million during the quarter, compared to analyst estimates of $8.32 million. Five Prime Therapeutics had a negative return on equity of 31.78% and a negative net margin of 356.39%. The business’s revenue was down 16.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.49) earnings per share.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/02/five-prime-therapeutics-inc-fprx-director-william-r-ringo-sells-600-shares.html.

A number of research analysts have recently commented on the company. Royal Bank Of Canada reiterated a “buy” rating and set a $41.00 target price on shares of Five Prime Therapeutics in a research report on Wednesday, October 25th. Zacks Investment Research upgraded Five Prime Therapeutics from a “sell” rating to a “buy” rating and set a $49.00 target price for the company in a research report on Monday, October 16th. BMO Capital Markets upgraded Five Prime Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Monday, October 16th. Jefferies Group LLC reiterated a “buy” rating and set a $52.00 target price on shares of Five Prime Therapeutics in a research report on Tuesday, September 12th. Finally, ValuEngine upgraded Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Two analysts have rated the stock with a sell rating and eight have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $54.83.

Several large investors have recently modified their holdings of FPRX. Creative Planning boosted its stake in shares of Five Prime Therapeutics by 0.8% in the second quarter. Creative Planning now owns 6,744 shares of the biotechnology company’s stock worth $203,000 after acquiring an additional 54 shares during the last quarter. Rockefeller Financial Services Inc. acquired a new stake in shares of Five Prime Therapeutics in the second quarter worth approximately $210,000. Legal & General Group Plc boosted its stake in shares of Five Prime Therapeutics by 3.1% in the second quarter. Legal & General Group Plc now owns 9,455 shares of the biotechnology company’s stock worth $288,000 after acquiring an additional 287 shares during the last quarter. Tudor Investment Corp ET AL boosted its stake in shares of Five Prime Therapeutics by 56.8% in the first quarter. Tudor Investment Corp ET AL now owns 8,033 shares of the biotechnology company’s stock worth $290,000 after acquiring an additional 2,910 shares during the last quarter. Finally, Virtu KCG Holdings LLC acquired a new stake in shares of Five Prime Therapeutics in the second quarter worth approximately $331,000. 84.01% of the stock is currently owned by hedge funds and other institutional investors.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Insider Buying and Selling by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.